MXPA00013014A - Dipe`tidos de oxamilos modificados en el extremo carboxi como inhibidores de la familia ice/ced-3 de proteasas de cisteinas. - Google Patents
Dipe`tidos de oxamilos modificados en el extremo carboxi como inhibidores de la familia ice/ced-3 de proteasas de cisteinas.Info
- Publication number
- MXPA00013014A MXPA00013014A MXPA00013014A MXPA00013014A MXPA00013014A MX PA00013014 A MXPA00013014 A MX PA00013014A MX PA00013014 A MXPA00013014 A MX PA00013014A MX PA00013014 A MXPA00013014 A MX PA00013014A MX PA00013014 A MXPA00013014 A MX PA00013014A
- Authority
- MX
- Mexico
- Prior art keywords
- ced
- ice
- family
- inhibitors
- cysteine proteases
- Prior art date
Links
- 101150055276 ced-3 gene Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000005927 Cysteine Proteases Human genes 0.000 title 1
- 108010005843 Cysteine Proteases Proteins 0.000 title 1
- 108010016626 Dipeptides Proteins 0.000 title 1
- KZAUOCCYDRDERY-UITAMQMPSA-N methyl (1z)-2-(dimethylamino)-n-(methylcarbamoyloxy)-2-oxoethanimidothioate Chemical group CNC(=O)O\N=C(/SC)C(=O)N(C)C KZAUOCCYDRDERY-UITAMQMPSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000005950 Oxamyl Substances 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3264—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
Abstract
Esta invencion esta dirigida a novedosos compuestos inhibidores de familia ICE/ced-3 de dipeptidos de oxamilo. Esta invencion tambien se dirige a composiciones farmaceuticas conteniendo estos compuestos, asi como al uso de tales composiciones en el tratamiento de pacientes que sufren de enfermedades inflamatorias, autoinmunes y neurodegenerativas, para la prevencion de lesion isquemica y para la conservacion de organos que van a experimentar un procedimiento de transplante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9168998P | 1998-07-02 | 1998-07-02 | |
US09/177,549 US6197750B1 (en) | 1998-07-02 | 1998-10-22 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
PCT/US1999/015074 WO2000001666A1 (en) | 1998-07-02 | 1999-07-01 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00013014A true MXPA00013014A (es) | 2004-04-02 |
Family
ID=26784233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00013014A MXPA00013014A (es) | 1998-07-02 | 1999-07-01 | Dipe`tidos de oxamilos modificados en el extremo carboxi como inhibidores de la familia ice/ced-3 de proteasas de cisteinas. |
Country Status (23)
Country | Link |
---|---|
US (1) | US6197750B1 (es) |
EP (2) | EP1091930B1 (es) |
JP (1) | JP3815968B2 (es) |
KR (1) | KR100804432B1 (es) |
CN (1) | CN1159289C (es) |
AT (2) | ATE442843T1 (es) |
AU (1) | AU752339B2 (es) |
BR (1) | BR9911675A (es) |
CA (1) | CA2336474C (es) |
CY (1) | CY1108088T1 (es) |
DE (2) | DE69941440D1 (es) |
DK (2) | DK1754475T3 (es) |
ES (2) | ES2276520T3 (es) |
HK (1) | HK1036616A1 (es) |
HU (1) | HUP0102898A3 (es) |
ID (1) | ID28263A (es) |
IL (1) | IL140554A0 (es) |
MX (1) | MXPA00013014A (es) |
NO (1) | NO20006544L (es) |
NZ (1) | NZ509025A (es) |
PL (1) | PL207578B1 (es) |
PT (1) | PT1091930E (es) |
WO (1) | WO2000001666A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1647279A3 (en) * | 1996-09-12 | 2006-04-26 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors |
US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
DE69939689D1 (de) * | 1998-03-19 | 2008-11-20 | Vertex Pharma | Caspase inhibitoren |
US6544951B2 (en) | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
DE60035037T2 (de) | 1999-04-09 | 2008-01-31 | Cytovia, Inc., San Diego | Caspase inhibitoren und ihre verwendung |
BR0013666A (pt) | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
KR20020058078A (ko) * | 1999-12-03 | 2002-07-12 | 우에노 도시오 | 옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제 |
US6790989B2 (en) * | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6515173B1 (en) | 2000-01-13 | 2003-02-04 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6867299B2 (en) | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
CA2406247A1 (en) * | 2000-04-17 | 2001-10-25 | Robert J. Ternansky | Inhibitors of the ice/ced-3 family of cysteine proteases |
US6525024B1 (en) | 2000-04-17 | 2003-02-25 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
AU2002245649A1 (en) * | 2001-03-02 | 2002-09-19 | Idun Pharmaceuticals, Inc. | Methods, compositions and kits for preserving antigenicity |
WO2003062192A1 (en) | 2002-01-17 | 2003-07-31 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
US7410956B2 (en) * | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
EP1499898A2 (en) * | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
EP1545509A4 (en) * | 2002-09-25 | 2008-10-22 | Univ Rochester | CASPASE HEMMER AS CANCER |
US7923433B2 (en) | 2002-10-09 | 2011-04-12 | Activx Biosciences, Inc. | Activity-based probes and methods of their preparation and use |
PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
BRPI0414313A (pt) * | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
US20050209162A1 (en) * | 2003-11-10 | 2005-09-22 | Amit Roy | Methods for monitoring IL-18 |
AU2005249503B2 (en) * | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
PT1725548E (pt) | 2004-03-12 | 2015-04-16 | Vertex Pharma | Processo e intermediários para a preparação de inibidores de caspase de acetal de ácido aspártico |
RU2412936C2 (ru) | 2004-11-24 | 2011-02-27 | Вертекс Фармасьютикалз Инкорпорейтед | Производные 3-[2-(3-ациламино-2-оксо-2н-пиридин-1-ил)-ацетиламино]-4-оксо-пентановой кислоты и их применение в качестве ингибиторов каспазы |
CN101217980A (zh) * | 2005-07-11 | 2008-07-09 | 辉瑞有限公司 | 治疗肝纤维化的抗madcam抗体和抗纤维化半胱天冬蛋白酶抑制剂的新组合 |
ATE529430T1 (de) * | 2005-07-28 | 2011-11-15 | Vertex Pharma | Caspase-hemmer-propharmaka |
PT2091910E (pt) * | 2006-12-06 | 2014-11-18 | Conatus Pharmaceuticals Inc | Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico |
JP6006908B2 (ja) | 2010-11-05 | 2016-10-12 | ブランダイス ユニバーシティBrandeis University | Ice阻害化合物およびその使用 |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
US10100037B2 (en) | 2013-03-15 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
ES2751652T3 (es) | 2014-05-12 | 2020-04-01 | Conatus Pharmaceuticals Inc | Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas |
US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
BR112019005985A2 (pt) | 2016-10-05 | 2019-06-25 | Novartis Ag | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico |
EP3510380B1 (en) | 2016-12-23 | 2023-11-08 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
AU2019233195A1 (en) | 2018-03-13 | 2020-09-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | A crystal of a caspase inhibitor |
CA3105352A1 (en) | 2018-06-29 | 2020-01-02 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
EP0618223A3 (en) * | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
TW494094B (en) | 1993-04-29 | 2002-07-11 | Vertex Pharma | Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same |
US5869519A (en) * | 1996-12-16 | 1999-02-09 | Idun Pharmaceuticals, Inc. | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US5968927A (en) * | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
US5877197A (en) * | 1996-12-16 | 1999-03-02 | Karanewsky; Donald S. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
-
1998
- 1998-10-22 US US09/177,549 patent/US6197750B1/en not_active Expired - Lifetime
-
1999
- 1999-07-01 DE DE69941440T patent/DE69941440D1/de not_active Expired - Lifetime
- 1999-07-01 EP EP99932211A patent/EP1091930B1/en not_active Expired - Lifetime
- 1999-07-01 EP EP06125650A patent/EP1754475B1/en not_active Expired - Lifetime
- 1999-07-01 DK DK06125650T patent/DK1754475T3/da active
- 1999-07-01 JP JP2000558071A patent/JP3815968B2/ja not_active Expired - Lifetime
- 1999-07-01 IL IL14055499A patent/IL140554A0/xx not_active IP Right Cessation
- 1999-07-01 PT PT99932211T patent/PT1091930E/pt unknown
- 1999-07-01 HU HU0102898A patent/HUP0102898A3/hu unknown
- 1999-07-01 ES ES99932211T patent/ES2276520T3/es not_active Expired - Lifetime
- 1999-07-01 PL PL345350A patent/PL207578B1/pl not_active IP Right Cessation
- 1999-07-01 BR BR9911675-8A patent/BR9911675A/pt not_active IP Right Cessation
- 1999-07-01 CA CA002336474A patent/CA2336474C/en not_active Expired - Lifetime
- 1999-07-01 AU AU48569/99A patent/AU752339B2/en not_active Expired
- 1999-07-01 NZ NZ509025A patent/NZ509025A/en not_active Application Discontinuation
- 1999-07-01 DK DK99932211T patent/DK1091930T3/da active
- 1999-07-01 DE DE69934405T patent/DE69934405T2/de not_active Expired - Lifetime
- 1999-07-01 AT AT06125650T patent/ATE442843T1/de not_active IP Right Cessation
- 1999-07-01 ID IDW20010254A patent/ID28263A/id unknown
- 1999-07-01 ES ES06125650T patent/ES2330663T3/es not_active Expired - Lifetime
- 1999-07-01 AT AT99932211T patent/ATE348096T1/de active
- 1999-07-01 KR KR1020007015074A patent/KR100804432B1/ko not_active IP Right Cessation
- 1999-07-01 CN CNB998100196A patent/CN1159289C/zh not_active Expired - Lifetime
- 1999-07-01 WO PCT/US1999/015074 patent/WO2000001666A1/en active IP Right Grant
- 1999-07-01 MX MXPA00013014A patent/MXPA00013014A/es active IP Right Grant
-
2000
- 2000-12-21 NO NO20006544A patent/NO20006544L/no unknown
-
2001
- 2001-10-18 HK HK01107291A patent/HK1036616A1/xx not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100251T patent/CY1108088T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA00013014A (es) | Dipe`tidos de oxamilos modificados en el extremo carboxi como inhibidores de la familia ice/ced-3 de proteasas de cisteinas. | |
WO2003072528A3 (en) | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | |
NO20011968L (no) | (Substituerte)acyl dipeptidyl-inhibitorer av ICE/ced-3 familien av cysteinproteaser | |
BR0008584A (pt) | 2-indolil(n-substituìdo)carbonildipeptìdeos modificados no terminal c como inibidores da famìlia ice/ced-3 das cisteìna proteases | |
WO2002057298A3 (en) | C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | |
IL128940A0 (en) | C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and pharmaceutical compositions containing them | |
SG158733A1 (en) | Cell adhesion inhibitors | |
IL122116A0 (en) | Polypeptide comprising kunitz-type serine protease inhibitor | |
IL116078A (en) | Substituted heterocyclic compounds capable of inhibiting serine proteases and pharmaceutical compositions containing them | |
WO1992011850A3 (en) | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration | |
BG101841A (en) | Cellular adhesion inhibitors | |
EA200401240A1 (ru) | Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов | |
MX9803851A (es) | Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. | |
AU4583597A (en) | Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes | |
MXPA03010179A (es) | Eteres de arilsulfonamida y metodos de uso de los mismos. | |
ATE229514T1 (de) | Macrocyclische verbindungen als metallproteaseinhibitoren | |
WO2001079162A3 (en) | INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | |
DE60215917D1 (de) | Tripepide und tripepdid-derivte zur behandlung von neurodegenerativen erkrankungen | |
WO2001034566A3 (en) | Protease inhibitors | |
WO2002011750A3 (en) | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway | |
MX2023000444A (es) | Composicion farmaceutica para el tratamiento del vitiligo. | |
ATE189391T1 (de) | Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer | |
AU2002239978A1 (en) | C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | |
TR200100124A2 (tr) | Askorbat ve lizin içeren sinerjistik bileşimler | |
UY25369A1 (es) | Procedimiento para preparar inhibidores de proteasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |